Thalia Therapeutics plc acquires Sanmirna Therapeutics Inc (2026)

Deal facts

Buyer: Thalia Therapeutics plc
Target: Sanmirna Therapeutics Inc
Deal value: Not disclosed
Announced: 17 July 2026
Status: Completed
Sector: Healthcare
Country: Not stated
Consideration: shares, loan-note

Sources

LSE_RNS_Investegate

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

17 Jul 2026CompletedClosed
Result of AGM and Completion of Acquisition
Disclaimer* 17 July 2026 Thalia Therapeutics plc ("Thalia" or the "Company") Result of AGM and Completion of Acquisition Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, is pleased to announce that at its annual general me
LSE RNS

OpinionExit Mode editorial

We see Thalia Therapeutics plc, a UK-listed healthcare group, complete a strategic acquisition of Sanmirna Therapeutics Inc, a US-based biotech, on 17 July 2026. The deal was paid for with a mix of Thalia shares and a loan-note, and the transaction is now recorded as completed. No monetary value was disclosed, but the structure tells us a lot about how cross-border deals are being financed in the sector.

Our view is that Thalia is using the share component to preserve cash while giving Sanmirna shareholders a stake in the combined business. The loan-note adds immediate funding without diluting existing shareholders further. This hybrid approach is increasingly common in healthcare where cash flow can be tight but growth-capital is essential. Because the buyer is a UK public company, the acquisition would have required clearance from the Competition and Markets Authority, and likely a review by US antitrust authorities. The fact that the deal is completed confirms those regulatory hurdles have been cleared, signalling that the CMA is willing to approve well-structured, sector-specific consolidations.

For the SME founder reading this, the transaction highlights two practical lessons. First, a clear intellectual-property portfolio and a credible pipeline can make a UK-based business an attractive acquisition partner for US targets. Second, having a financing plan that blends equity with debt-like instruments can smooth the path to a deal while limiting immediate shareholder dilution. Founders should also be aware that change-of-control covenants and potential earn-out provisions are typical in such deals, even if they were not disclosed here.

Take action this week by mapping your own capital structure against a share-plus-loan-note model and arranging a brief discussion with your legal adviser about the CMA’s turnover thresholds for a required review. This will put you in a stronger position if a cross-border strategic acquisition ever becomes part of your growth plan.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Thalia Therapeutics plc All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history